Best Life Sciences Companies in Nottingham, United Kingdom
The 35 best Life Sciences companies in Nottingham, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Locate Bio.
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
Ranked: Best Life Sciences companies in Nottingham
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Locate Bio Developer next generation of orthobiologics products for the treatment of injuries | $32M | 30 mo ago | 12 12 → 27 (+125%) | Kevin Shakesheff Co-Founder | Series A | — | — |
| 2 | IsomAb Developer of antibodies against vascular diseases | $10M | 31 mo ago | 3 | David Bates Chief Scientific Officer and Founder | Series A | — | — |
| 3 | Exco InTouch Mobile phone applications for clinical trial management and patient engagement | $10M | 141 mo ago | 135 | — | Acqui-Hired | 7 patents Adaptive mobile health content delivery platforms for disease-specific patient care | — |
| 4 | CellAura Fluorescent screening products for specific cellular targets | $8M | 218 mo ago | — | Dai Hayward CEO | Deadpooled | 7 patents Patents concentrated in chemistry & materials | — |
| 5 | Monica Healthcare Developer of wearable devices for fetal and maternal management | $8M | 139 mo ago | 8 | — | Acqui-Hired | 63 patents Patents concentrated in health & consumer products | — |
| 6 | NuVision Developer of an ophthalmic therapies for ocular surface disease 48Product top 14%Innovation top 34%Growth top 35%Funding top 43% All 9 signals ▾Producttop 14% Innovationtop 34% Growthtop 35% Fundingtop 43% Techtop 43% Moattop 48% Talentbottom 49% Globalbottom 32% Marketbottom 28% Product: 4 distinct product lines · Company stage: Public Innovation: 4 product lines rank vs industry peers · Fliar Intelligence Index 48/100 | $7M | 7 mo ago | 14 14 → 25 (+79%) | Harminder Dua Co-Founder | Public | — | — |
| 7 | CompanDX Developer of a patented systems biology and bioinformatics platform | $6M | 169 mo ago | 3 | Simon Haworth CEO | Series A | 2 patents Diagnostic biomarkers for infectious and neurodegenerative disease detection | — |
| 8 | Chain Biotech Developer of microbiome-based oral immunotherapies | $6M | 39 mo ago | 8 | — | Seed | — | — |
| 9 | Exonate Developer of small molecule drugs for retinal vascular diseases | $4M | 92 mo ago | 17 17 → 16 (-6%) | — | Seed | 54 patents Small-molecule kinase inhibitors and ocular anti‑angiogenic agents for therapeutic use. | — |
| 10 | PHARMASEAL Developer of a SaaS based platform for biopharmaceutical companies to manage their clinical trials | $3M | 72 mo ago | 8 | Daljit Cheema Founder & CEO | Seed | — | — |
| 11 | Critical Pharmaceuticals Reformulates biologic drugs using proprietary drug delivery technologies. | $3M | 136 mo ago | 7 | Steven Howdle Founder & CEO | Deadpooled | 57 patents Microparticle and solid polymer matrix drug delivery formulation technologies | — |
| 12 | Haemostatix Developing new class of peptide based coagulant | $2M | 134 mo ago | 11,995 | Ben Nichols CEO | Acquired | 89 patents Hemostatic medical compositions and bioactive wound dressings for bleeding control | — |
| 13 | SurePulse Vital sign monitoring solution for babies | $1M | 74 mo ago | 9 | James Carpenter CEO | Seed | — | 1 launch |
| 14 | Olberon Developer of venous access and diagnostic devices | $117K | 99 mo ago | 2 | Arash Bakhtyari Founder & CEO | Funding Raised | 36 patents Intravenous access and needle guidance devices for improved cannulation and fluid management | — |
Top 12 Life Sciences companies in Nottingham
#1
Public · Nottingham, England · founded 2015 · 14 employees$6.9Mraised▾
Developer of an ophthalmic therapies for ocular surface disease. The company’s product Omnigen is a biological wound dressing that aids the regeneration and healing of the surface of the eye. It is a human amniotic membrane-derived dry preserved biological matrix intended for wound care. Also has an OmniLenz bandage contact lens that allows suture-free transplantation.
- Feb 2026Series B$6.6M
- Mar 2023Series A$1.3M
- Jul 2021Series A$2.5M
- Sep 2019Seed$1.7M
#2
Series A · Nottingham, England · founded 2001 · 12 employees$31.6Mraised▾
Developer next generation of orthobiologics products for the treatment of injuries. It offers proprietary and precisely highly engineered tissue scaffolds made of naturally derived materials, to address the repair and regeneration of both bone and cartilage. The products include LDGraft which is an rhBMP-2 product for lumbar interbody fusion procedures. It also has CertOss and OsteoMime in the orthobiologic pipeline.
- Mar 2024Series A$11.8M
- Sep 2021Series A$13.8M
- Jul 2020Seed$2.8M
- May 2019Seed$2.6M
#3
Series A · Nottingham, England · founded 2022 · 3 employees$10.5Mraised▾
Developer of antibodies against vascular diseases. It is developing isoform-specific, humanized IgG1-based antibodies using a combined bioinformatics-based platform against Vascular Endothelial Growth Factor A (VEGF-A).
- Feb 2024Series A$9.5M
- Dec 2022Seed$1M
#4
Seed · Nottingham, England · founded 2014 · 8 employees$5.9Mraised▾
Developer of microbiome-based oral immunotherapies. The company uses Clostridium Assisted Drug Development (CADD) platform combines precision engineering with a superior host bacterium to effectively deliver therapeutic payloads to the lower gastrointestinal (GI) tract.
- Jun 2023Seed$2.3M
- Sep 2022Seed$566.4K
- Sep 2021Seed$820.2K
- Oct 2019Seed$322.8K
#5
Acqui-Hired · Nottingham, England · founded 2005 · 8 employees$7.6Mraised▾
Developer of wearable devices for fetal and maternal management. The product uses wireless technologies to facilitate globally accessible obstetric services in the home and hospital. The patented technology is based on the acquisition of electrophysiological signals that can be passively detected by electrodes positioned on the maternal abdomen.
- Jan 2015Grant (prize money)$377K
- Jan 2015Series A$3M
- Jun 2013Series A—
- Apr 2009Series A$1.7M
#6
Acqui-Hired · Nottingham, England · founded 2004 · 135 employees$9.7Mraised▾
Exco InTouch provides digital patient engagement and data capture solutions for clinical research and healthcare providers. It offers channels of communication; facilitating the collection of quality data and improving outcomes for sponsors, clinical research organizations, sites and patients.
- Dec 2014Series A$5M
- 2012Conventional Debt$3.2M
- Sep 2011Series A$4.7M
#7
Deadpooled · Nottingham, England · founded 2006$7.6Mraised▾
Fluorescent screening products for specific cellular targets. Its portfolio products include G-protein coupled receptors (GPCRs) that have applications in life sciences research and drug discovery. It claims to have experience in the production of high-quality fluorescent ligands with pharmacological characterization for use in high throughput and high content screening platforms. Its GPCRs include radioligand and antibody substitutes, for high content screening (HCS), flow cytometry and FACS, receptor pharmacology and dimerization, and ligand binding kinetics.
- Jul 2008Series A$874.3K
- Oct 2007Series A$6.7M
#8
Seed · Nottingham, England · founded 2013 · 17 employees$4.4Mraised▾
Developer of small molecule drugs for retinal vascular diseases. The lead program is focused on diabetic macular edema which inhibits the production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing.
- Jan 2019Seed$1.9M
- Feb 2017Grant (prize money)$6.1M
- Nov 2016Seed$1.9M
- Oct 2015Seed—
#9
Series A · Nottingham, England · founded 2010 · 3 employees$6.1Mraised▾
Developer of a patented systems biology and bioinformatics platform. They have developed a patented systems biology and bioinformatics solution using which they are identifying new drug discovery targets. It offers single target data mining, integrated analysis, and network interface modeling.
- Jul 2012Series A$6.1M
#10
Seed · Nottingham, England · founded 2016 · 8 employees$2.7Mraised▾
PHARMASEAL is a SaaS-based B2B clinical trial governance platform for biopharmaceutical companies to manage their clinical trials. The company is developing a cloud-based trial management platform that allows clinical trial operators to manage and monitor their clinical trials in accordance with good clinical practice (GCP) regulatory standards. The company also plans to develop modules such as a patient safety tool & a license and regulatory management tool. The company has developed a product called Engility that assist with the clinical trail study and task management.
- Sep 2020Seed$673.1K
- May 2019Seed$1.3M
- Jan 2018Seed$695.8K
#11
Acquired · Nottingham, England · founded 2003 · 11995 employees$2.4Mraised▾
Haemostatix has developed a new class of peptide-based coagulant, or "haemostat", for the control of bleeding. The company has pioneered a new approach to haemostasis that is based on a peptide that binds to the protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical products to treat surgical bleeding. Haemostatix's pipeline includes PeproStat™ Liquid, a topical liquid haemostat that is applied to wounds to control bleeding during surgery; and HXP12 ReadyFlow™, a flowable and transparent haemostatic gel that can be applied to irregular bleeding sites.
- Jun 2015Grant (prize money)$31.5K
- Nov 2012Series A$1.3M
- Oct 2012Grant (prize money)$2.2M
- Jun 2011Series A$405.5K
#12
Deadpooled · Nottingham, England · founded 2002 · 7 employees$2.6Mraised▾
Critical Pharmaceuticals reformulated biologic drugs using proprietary drug delivery technologies. It has two platform technologies: CriticalSorb which is an excipient that enables nasal delivery of existing drugs. and CriticalMix which uses supercritical carbon dixide to enable mixing of drug and polymer for controlled-release formulations. Currently, the company has a nasal growth hormone formulation, nasal Parathyroid Hormone PTH 1-34, long acting growth hormone and long acting risperidone in the pipeline.
- May 2015Grant (prize money)$56K
- Feb 2007Series A$1.2M
- Jan 2005Series A$1.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Nottingham is moving
A read on the academic research around Biotechnology in Nottingham — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 42 papers.
- University of Nottingham26
- University of Nottingham Ningbo China7
- University of Nottingham Malaysia Campus4
- Nottingham Trent University3
- NIHR Nottingham Digestive Diseases Biomedical Research Unit1
- Cell culture3
- Genome2
- genomic DNA2
- Antibody2
- Phenotype2
- Function (biology)2
- Arabidopsis2
- Downregulation and upregulation2
- Metagenomics2
- Protein quality1
- Disease2
- Outbreak2
- Quality (philosophy)2
- Yield (engineering)2
- Selenium1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.